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Abstract
Production and manufacturing methods and the food carrier may influence the properties of probiotic strains, and have an impact on the
outcome of clinical intervention studies. The aim of the present study was to establish whether the properties of a specific probiotic strain,
Lactobacillus rhamnosus GG, may differ depending on the product and source of the strain. In total, fifteen different L. rhamnosus isolates,
among them fourteen labelled as L. rhamnosus GG, were isolated from specific probiotic products. The micro-organisms were phenoty-
pically and genotypically characterised. Their adhesion properties were compared using the human intestinal mucus model, and the
ability of the isolates to influence model pathogen adhesion to human colonic mucus was assessed. All L. rhamnosus isolates used
were confirmed as members of the species L. rhamnosus. Except the reference strain OL, all L. rhamnosus isolates showed randomly
amplified polymorphic DNA, enterobacterial repetitive intergenic consensus and pulsed-field gel electrophoresis profiles identical to
that of L. rhamnosus GG (ATCC 53103). All L. rhamnosus isolates showed similar tolerance to acid and were able to bind to human colonic
mucus. However, pathogen exclusion by inhibition and competition varied significantly among the different L. rhamnosus isolates
and pathogens tested. The results suggest that different sources of the same probiotic may have significantly altered strain properties.
This should be considered in in vivo studies on human subjects and also for quality control of probiotic products.
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In 2002, a joint FAO/WHO Working Group defined a
probiotic as a ‘live microorganism which when administered
in adequate amounts confers a health benefit on the host’(1).
Until now, specific probiotics have been selected and
characterised based on their in vitro properties, for
example tolerance to gastrointestinal conditions, adhesion
to the intestinal mucus or epithelial cells and competitive
exclusion of target pathogens(2–4). Unfortunately, published
information frequently lacks accurate information on strain
identity and characteristics, for example International
Culture Collection deposits and deposit numbers, on
the one hand, and the mode of administration and the
preclinical documentation and the selection criteria on the
other. This makes strain comparison difficult and may
influence the results of clinical intervention studies.
We have extended this concern to the food matrix used
to deliver the probiotic to the study subject, providing
experimental evidence that the impact of Lactobacillus
rhamnosus GG (ATCC 53103) on antigen transport depends
on the quality of protein, unhydrolysed v. hydrolysed(5)
in the diet.
One further cause of variation in the outcomes of clinical
studies, beyond differences in populations, selection criteria
and study design, may arise when different production
conditions, growth media, drying conditions or cryoprotec-
tants are used for the same strain or when a successful
probiotic is combined with other bacteria or strains.
For example, the adhesion properties of the L. rhamnosus
GG strain (ATCC 53103) have been shown to depend on
the composition of the growth media and the number of
starter culture transfers(6). Clinical and immunological
effects were not achieved when L. rhamnosus GG was
combined with L. rhamnosus LC705, Bifidobacterium
breve Bb99 and Propionibacterium freudenreichii ssp.
shermanii(7). Similarly, as far back as in 1983, a distinction
in the clinical outcome for L. acidophilus was shown to
depend on the production lot(8).
The use of probiotics is currently extending from
research to recommendations(9,10), but rigorous scientific
effort is still required to validate specific strains with anti-
allergic potential for preventive and therapeutic appli-
cations. The production of functional probiotic foods
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presupposes stability of strain features in the final product.
This requirement is emphasised in treating young infants
with impaired gut barrier function, aberrant gut microbiota
and sensitisation to dietary substances. For this purpose,
we evaluated in the present study the strain characteristics,
tolerance to acid pH and the adhesion and competi-
tive exclusion properties of putative L. rhamnosus GG
isolates obtained from different commercial products and
production lots used in clinical intervention studies. As a
prerequisite step, each isolate was genotypically and
phenotypically characterised to ensure identical profiles,
also excluding the possibility of contamination or misiden-
tification of the strain obtained from different probiotic
products.
We hypothesised that there are differences among
the properties of the same probiotic strain, which depend
on the production processes using different methods
and media, and these influence strain properties with a
consequent impact on the clinical and nutritional proper-
ties of probiotics.
Experimental methods
Bacterial isolates and culture conditions
Altogether thirteen L. rhamnosus isolates claimed to be
L. rhamnosus GG (ATCC 53103) were isolated from
different probiotic products from different countries
(identification codes: AL, BL, CL, DL, EL, FL, HL, IL, JL,
KL, LL, ML and NL). Among them, four isolates (AL, EL,
FL and NL) were isolated from capsule products from
different countries, two isolates (LL and ML) were derived
from commercial infant foods, three isolates (DL, HL and
KL) were isolated from freeze-dried powders of different
products and four isolates (BL, CL, IL and JL) were
provided from soft agar. For comparison, the original
L. rhamnosus GG (original L. rhamnosus GG strain isolate
donated by Professor Sherwood Gorbach of Tufts
University, Boston, MA, USA) was included. The original
L. rhamnosus GG strain is the foundation strain from
which other cultures used in probiotic products were
derived. An additional commercial probiotic L. rhamnosus
strain (identification code OL) of the same species but
known to be phenotypically different from L. rhamnosus
GG was included as an external reference strain.
The bacterial pathogens used were Cronobacter sakaza-
kii (ATCC 29544), Staphylococcus aureus (DSM 20231),
Clostridium perfringens (DSM 756) and Salmonella enter-
ica serovar Typhimurium (ATCC 12028).
The L. rhamnosus isolates were grown in de Man,
Rogosa and Sharpe broth (Oxoid Limited, Basingstoke,
Hampshire, UK) and incubated at 378C under anaerobic
conditions (10 % H2, 10 % CO2 and 80 % N2; Concept
400 anaerobic chamber, Ruskin Technology, Leeds,
UK). For adhesion, competitive exclusion, displacement
and inhibition assays, the isolates were grown for 18 h,
harvested and then washed twice with PBS buffer.
All micro-organisms were metabolically labelled by the
addition of 10ml/ml tritiated thymidine (5-3H-thymidine
1·0 mCi/ml; Amersham Biosciences, Little Chalfont, Bucks,
UK) to the media.
Species identity of isolates by partial sequence
analysis of the 16S rRNA gene
The L. rhamnosus isolates used in the present study were
identified at the species level by partial sequence analysis
of the 16S rRNA gene, followed by Blast analysis. In brief,
micro-organisms were grown overnight, 1 ml of cells
was harvested and the DNA was extracted using the
GenElutee Bacterial Genomic DNA Kit (Sigma, St Louis,
MO, USA) following the manufacturer’s instructions. Partial
amplification of the 16S rRNA gene and species identifi-
cation were carried out as described previously(11). Ampli-
fied PCR products were purified using the GenElutee PCR
Clean-Up Kit (Sigma), and automated sequencing of the
amplicons was carried out at Secugen SL (Madrid, Spain)
in an automated sequencer ABI Prism (Applied Biosystems,
Foster City, CA, USA). The sequences obtained were
compared with those held at the GenBank database by
using the Blast application at the NCBI webpage.
Genetic typing of the isolates
Randomly amplified polymorphic DNA-PCR. DNA
extracts from the different L. rhamnosus isolates were used
for strain typification by randomly amplified polymorphic
DNA analysis using previously described conditions and
the primer for L. rhamnosus (12) (Sigma Genosys, St Louis,
MO, USA). PCR assays were run in a Unocycler (VWR Inter-
national Eurolab S.L., Barcelona, Spain) thermocycler.
Amplification products were subjected to electrophoresis
on 1 % agarose (Sigma), and the gels were stained and visu-
alised by ethidium bromide staining.
Enterobacterial repetitive intergenic consensus-PCR.
Enterobacterial repetitive intergenic consensus-PCR is
based on the use of oligonucleotides targeting short repeti-
tive sequences distributed throughout the bacterial
genome. DNA was amplified using primers 50-ATGTAAGC-
TCCTGGGGATTCAC-30 and 50-AAGTAAGTGACTGGGGT-
GAGCG-30 (Sigma Genosys) as described previously(13).
DNA restriction patterns by pulsed-field gel electro-
phoresis. The L. rhamnosus isolates were typified using
analysis of DNA restriction patterns by pulsed-field gel
electrophoresis (PFGE). Intact high-molecular weight
genomic DNA was isolated and digested in agarose plugs.
Cells were grown to an OD600 of 1·5, harvested by centrifu-
gation, washed three times in buffer Tris–HCl (10 mM)–
EDTA (1 mM), pH 8·0, and resuspended in 500ml of the
same solution. To form agarose plugs, the cell suspension
was heated to 508C, mixed with an equal volume of 2 %
PFGE agarose (Bio-Rad Laboratories, Richmond, CA, USA)
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in 0·5 £ Tris–borate–EDTA buffer and added to moulds.
The plugs were incubated for 24 h at 378C in 1 ml lysis
buffer (per plug) containing 50mM-EDTA (pH 8·0), N-lauryl-
sarcosine (0·5mg/ml; Sigma), Brij58 (5mg/ml; Sigma), deoxy-
cholate (2mg/ml; Sigma), lysozyme (2mg/ml; Sigma),
mutanolysin (15 U/ml; Sigma) and RNase (2mg/ml;
Sigma) and were then deproteinised by incubation at
508C for 24 h in a solution containing 0·5 M-EDTA pH
(8·0), 40 mM-Tris–HCl (pH 8·0), 1 % (w/v) SDS (Sigma)
and proteinase K (1·5 mg/ml; Sigma). They were finally
washed for 1 h in Tris–HCl (10 mM)–EDTA (1 mM), pH 8·0,
and incubated for 24 h at 378C in Tris–HCl (10 mM)–
EDTA (1 mM), pH 8·0, containing Pefabloc SC (0·29 mg/ml;
Merck, Darmstadt, Germany).
Thin slices of the agarose plugs were cut and washed six
times for 30 min at room temperature in Tris–HCl
(10 mM)–EDTA (1 mM), pH 8·0, buffer. DNA within the
plugs was digested with 20 U of the appropriate restriction
enzyme in 200ml of the buffer recommended by the sup-
plier. Two different restriction enzymes, SfiI and NotI,
were tested. Electrophoresis was carried out at 6 V/cm
and 148C using a CHEF DRII apparatus (Bio-Rad Labora-
tories) in 1 % PFGE certified agarose (Bio-Rad Laboratories)
gels with 0·5 £ Tris–borate–EDTA buffer. Pulse times
ranged from 2 to 30 s during the 24 h electrophoresis.
A DNA pulse marker (LowRange PFG Marker N0350S;
New England Biolabs, Hitchin, Herts, UK) was used as
molecular size standard. Gels were stained and visualised
by ethidium bromide staining.
Characterisation of the isolates by carbohydrate
fermentation profiles
The fermentation ability of the L. rhamnosus isolates was
obtained in API 50 CH strips (Bio-Me´rieux, Marcy l’Etoile,
France) following the manufacturer’s instructions.
Tolerance to acid
Bacterial cultures (5 ml) were grown overnight, cells were
harvested, washed twice with 0·85 % NaCl and resus-
pended in 500ml of the same solution; 100ml of the
bacterial suspensions (approximately 1 £ 108 cells) were
added to 900ml of simulated gastric juice (125 mM-NaCl,
7 mM-KCl, 45 mM-NaHCO3 and pepsin (3 g/l; Sigma))
adjusted to pH 2·0 or 2·5 with HCl. Suspensions were
then incubated for 90 min. Plate counts were made at
time point 0 and after 90 min of incubation.
In vitro assay of adhesion to human intestinal mucus
Human intestinal mucus was obtained as described else-
where(3) from the human colon. Colonic mucus was
dissolved (0·5 mg protein/ml) in HEPES–Hanks buffer
(10 mM-HEPES, pH 7·4). Radiolabelled bacterial
absorbance (A600 nm) was adjusted to 0·25 (SD 0·05) to
standardise the bacterial concentration (108 cells/ml).
The adhesion assessment of the L. rhamnosus isolates
and bacterial pathogens was carried out as described
previously(14). Adhesion was expressed as the percentage
of radioactivity recovered after adhesion relative to
the radioactivity of the bacterial suspension added to the
immobilised mucus. Adhesion was determined in three
independent experiments, and each assay was performed
in triplicate to calculate intra-assay variation.
Exclusion by inhibition assay
To test the ability of the L. rhamnosus isolates to inhibit
the adhesion of pathogens, the procedure described by
Collado et al.(14,15) was used. In brief, unlabelled isolates
(108 cells/ml) were added to the wells and incubated
for 1 h at 378C; they were then removed by washing
with HEPES–Hanks buffer. Radiolabelled pathogens
(108 cells/ml) were then added to the wells and incubated
at 378C for 1 h. Thereafter, the wells were washed, and the
bound bacteria were recovered after lysis. Radioactivity
was measured by liquid scintillation. The percentage of
adhesion inhibition was calculated as the difference
between the adhesion of the pathogen in the absence
and presence of the different isolates. Inhibition was deter-
mined in three independent experiments, and each assay
was performed in triplicate.
Exclusion by displacement assay
The ability of the L. rhamnosus isolates studied to displace
pathogens already adhered was assessed according to
Collado et al.(14,15). Radiolabelled pathogens were added
to the wells containing mucus. After washing and removal
of unbound pathogens, non-radiolabelled isolates were
added. Wells were incubated and washed; thereafter,
bound bacteria were recovered after lysis and radioactivity
was measured. Displacement of pathogens was calculated
as the difference between the adhesion of pathogens
before and after the addition of the L. rhamnosus isolates.
At least three independent experiments were carried out.
Each assay was performed in triplicate to calculate intra-
assay variation.
Exclusion by competition assay
Competitive inhibition of the model pathogens by the
L. rhamnosus isolates studied was determined as described
previously(15). For the competition test, equal quantities of
a given bacterial suspension of isolates and radiolabelled
pathogens were mixed and then added to the intestinal
mucus and incubated as indicated previously. The cells
of the pathogen bound to the mucus were then removed,
and adhesion was calculated as described earlier.
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Statistical analysis
The adhesion (%) measured in different conditions was the
primary endpoint. One-way ANOVA was used to test the
overall difference in the adhesion properties between
strains. When P,0·10, Dunnett’s (two-tailed) t test was
used to compare each strain with the reference strain
L. rhamnosus GG without any other pairwise comparisons.
The cut-off point was not strictly determined at 0·05 to indi-
cate statistical significance due to the small sample size and
large type II error. Based on Dunnett’s t test, the exact
P values are given, and in which both 0·05 and 0·10
were used as cut-off points to indicate the degree of statisti-
cal significance in the difference between strains.
Statistical analysis was conducted using SPSS 18.0 soft-
ware (SPSS, Inc., Chicago, IL, USA).
Results
Identification at the species level
All L. rhamnosus isolates used were confirmed as members
of the species L. rhamnosus by partial sequencing of the
16S rDNA. Sequence analysis showed 100 % sequence
homology among the different L. rhamnosus isolates
studied as well as with L. rhamnosus 16S rDNA sequences
held in the databases (data not shown).
Genotypic and phenotypic characterisation of the isolates
All L. rhamnosus isolates, except the reference strain OL,
showed randomly amplified polymorphic DNA, enterobac-
terial repetitive intergenic consensus and PFGE profiles
identical to that of the original L. rhamnosus GG isolate
obtained from Professors Gorbach and Goldin. These
three techniques allowed differentiation of the isolate
L. rhamnosus OL from the other L. rhamnosus isolates.
With regard to phenotypic characterisation, none of
the L. rhamnosus isolates fermented glycerol, erythritol,
L-arabinose, D-xylose, L-xylose, D-adonitol, methyl-b-
D-xylopyranoside, inositol, methyl-a-D-mannopyranoside,
D-melibiose, D-saccharose, inulin, D-raffinose, starch,
glycogen, xylitol, D-turanose, D-lyxose, D-fucose, D-arabi-
tol, L-arabitol, 2-ketogluconate or 5-ketogluconate. All
isolates fermented D-arabinose, D-ribose, D-galactose,
D-glucose, D-mannitol, D-fructose, D-mannose, dulcitol,
D-sorbitol, N-acetyl glucosamine, amygdalin, arbutin,
esculin, salicin, D-cellobiose, D-trehalose, D-melezitose,
gentiobiose, D-tagatose, L-fucose and gluconate. All
putative L. rhamnosus isolates showed identical sugar
fermentation profiles, being different from those of the
reference strain OL, which in addition was able to
ferment L-sorbose, L-rhamnose, methyl-a-D-glucopyrano-
side, D-maltose and D-lactose.
Low pH tolerance
Tolerance to acidic pH (pH 2 and 2·5) varied from 43·0 to
79·1 % and showed no significant differences (P.0·05)
among the tested L. rhamnosus isolates.
In vitro adhesion assay to colonic mucus
All the tested L. rhamnosus isolates had a good ability to
adhere to human colonic mucus, although this varied
between different isolates. The adherence of the original
L. rhamnosus GG was 19 (SD 7·5) %, and that of the
other isolates varied from 12·1 to 24·3 %. Only the adhesion
of the reference strain OL differed significantly from that of
the original L. rhamnosus GG (P¼0·01), and it also showed
the lowest percentage of adhesion among all the isolates
tested (data not shown).
Among the pathogenic strains tested, the most marked
ability to adhere to colonic mucus was detected for
S. aureus (10·2 (SD 3·0) %), followed by C. perfringens
(4 (SD 3·1) %), S. enterica serovar Typhimurium (2·4 (SD
0·7) %) and C. sakazakii (2 (SD 0·7) %).
Exclusion by inhibition assay
The ability to inhibit the adhesion of pathogens to colonic
mucus by the L. rhamnosus isolates differed significantly
(see Fig. 1). The original L. rhamnosus GG was able to
inhibit all pathogens tested, and this micro-organism
reduced the adhesion of C. sakazakii (31 %), S. enterica
serovar Typhimurium (25 %), C. perfringens (25 %) and
S. aureus (24 %).
Differences were between L. rhamnosus isolates in the
adhesion of C. sakazakii, S. enterica serovar Typhimurium
and C. perfringens (ANOVA, P,0·001 for each) but not in
the adhesion of S. aureus (P¼0·352).
Four L. rhamnosus isolates (AL, LL, ML and NL)
showed different inhibition (P¼0·083, P¼0·015, P,0·001,
P¼0·025, respectively) of C. sakazakii compared with
the original L. rhamnosus GG. The isolate ML, again,
differed (P,0·001) from the original L. rhamnosus GG in
the adhesion inhibition of S. enterica serovar Typhimurium.
Two L. rhamnosus isolates (ML and OL) differed (P,0·001,
P¼0·032, respectively) in the adhesion inhibition of
C. perfringens from the original L. rhamnosus GG.
The adhesion inhibition of S. aureus did not differ
between the tested L. rhamnosus isolates and the original
L. rhamnosus GG.
Exclusion by displacement assay
All L. rhamnosus isolates were able to displace the pread-
hered model pathogens tested in colonic mucus. Differ-
ences were between L. rhamnosus isolates in the
adhesion of C. sakazakii, S. enterica serovar Typhimurium
(ANOVA, P¼0·063, 0·001, respectively) but not between
Ł. Grzes´kowiak et al.890
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C. perfringens and S. aureus (ANOVA, P¼0·128, 0·717,
respectively). The original L. rhamnosus GG displaced
54 % of adhered S. enterica serovar Typhimurium, and it
differed (P¼0·084) from the L. rhamnosus LL isolate.
C. perfringens was displaced by 33 % and S. aureus by
20 % by the original L. rhamnosus GG, and all the other
isolates showed no difference in the displacement from
the original L. rhamnosus GG. The original L. rhamnosus
GG displaced C. sakazakii by 12 %, differing (P¼0·082,
0·009, 0·017, 0·013, 0·068, 0·019, 0·01, 0·092, 0·051, respect-
ively) from the other study isolates AL, BL, CL, DL, EL, HL,
IL, KL and NL. The results are shown in Fig. 2.
Exclusion by competition assay
The inhibition by competition varied among the L. rham-
nosus isolates and pathogens tested. The relevant data
are shown in Fig. 3. The presence of some isolates
increased the adhesion of C. sakazakii, S. enterica serovar
Typhimurium and C. perfringens to colonic mucus. All but
one isolate (BL) was able to reduce the adhesion of
S. aureus. Differences were between L. rhamnosus isolates
in the adhesion of C. sakazakii, S. enterica serovar
Typhimurium, C. perfringens and S. aureus (ANOVA,
P,0·001, P,0·001, P¼0·005, P¼0·023, respectively).
The original L. rhamnosus GG showed inhibition abilities
for all pathogens tested. This micro-organism inhibited
the adhesion of C. perfringens in 47 %, being different
(P¼0·057, 0·059, 0·07, 0·091, respectively) from the BL,
LL, ML and NL isolates; S. aureus in 39 %, being different
(P¼0·019) from the BL isolate; S. enterica serovar Typhi-
murium in 5 %, being different (P¼0·064, 0·014, 0·026,
respectively) from the IL, ML and NL isolates; C. sakazakii
in 9 %, showing a difference (P¼0·001, P¼0·003, P¼0·048,
P¼0·001, P,0·001, P¼0·079, respectively) from the AL,
DL, LL, ML, NL isolates and the reference strain OL.
Discussion
The term ‘probiotic’ per se implies a health benefit. Based
on the definition of probiotics, consumption of these
bacteria present in food products should exert a range
of health-promoting effects in the host(1). In several
meta-analyses and reviews, however, strains with no such
documentation are reported along with true probio-
tics(16,17). Moreover, confusion is caused by reporting on
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Fig. 1. Inhibition of the adhesion to colonic mucus of pathogenic bacteria by the tested Lactobacillus rhamnosus isolates. Results are expressed as percentages
with regard to the inhibition obtained with the original L. rhamnosus GG isolate donated by Professor S. Gorbach. Values on the X-axis higher than 0 indicate
adhesion inhibition higher than the original L. rhamnosus GG, and those lower than 0 indicate adhesion inhibition lower than the original L. rhamnosus GG.
Adhesion inhibition significantly different from the original L. rhamnosus GG (* if 0·05 # P,0·10 and ** if P,0·05). Values are means, with standard
errors represented by vertical bars. The OL indicates the external reference L. rhamnosus strain. C. sakazakii, Cronobacter sakazakii; S. enterica ser., Salmonella
enterica serovar; C. perfringens, Clostridium perfringens; S. aureus, Staphylococcus aureus. Identification codes: AL, BL, CL, DL, EL, FL, HL, IL, JL, KL, LL,
ML and NL.
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the effect of probiotic strains and their combinations
together. Indeed, scientifically it is not surprising that
different micro-organisms have different effects.
We demonstrate in the present study, for the first
time, the differences in the in vitro properties of several
L. rhamnosus GG isolates from different probiotic
products. As a preceding step, all micro-organisms were
genotypically and phenotypically characterised to ensure
that all putative L. rhamnosus GG isolates had identical
profiles, obviating any contamination or misidentification
of the isolates used in the different products. All putative
L. rhamnosus GG isolatesweremembersof the L. rhamnosus
group proved by the use of profiling techniques such as
randomly amplified polymorphic DNA-PCR, enterobacter-
ial repetitive intergenic consensus-PCR and PFGE, and
they showed profiles identical to that of the original
L. rhamnosus GG isolate. The genotypic and phenotypic
characterisation allowed distinction of the external refer-
ence strain OL from the L. rhamnosus isolates.
Adherence of bacteria to intestinal mucus or epithelium
is known to be a prerequisite for colonisation and infection
of the gastrointestinal tract by many pathogens(18).
The adherent probiotic strains may at least temporarily
colonise the gastrointestinal tract and inhibit or compete
with pathogens(19). Several reports have described
the adhesion abilities of probiotic strains and also their
inhibitory effects on model pathogen adhesion to human
mucus(14,20,21). Variations in these properties may affect
the clinical outcome of intervention studies. In the present
study, all tested L. rhamnosus isolates showed the ability to
adhere to human colonic mucus, and the adhesion ability
of different isolates varied but did not differ significantly.
Potentially, the preculturing may have decreased the
differences, and thus other adhesion assays without
the preculturing step should be considered. However, all
isolates had significantly higher adhesion ability than that
of the reference strain.
The model pathogen exclusion results varied signifi-
cantly and depended on the isolate in question. The results
indicate differences in these important properties of pro-
biotics among the different L. rhamnosus isolates obtained
from different sources. Moreover, conducting our analyses
required growing the different isolates under the same
standardised laboratory conditions. Despite this culture
step, which may have decreased the differences in physio-
logical properties of the strain or the effect of different
excipients used during manufacturing of the products,
our observations suggest that the in vitro properties of
probiotics may vary depending on the production con-
ditions used for the same probiotic strain.
The present findings indicate that different isolates of the
same strain may possess different properties which may
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Fig. 2. Displacement of the adhesion to colonic mucus of pathogenic bacteria by the tested Lactobacillus rhamnosus isolates. Results are expressed as percen-
tages with regard to the displacement obtained with the original L. rhamnosus GG isolate donated by Professor S. Gorbach. Values on the X-axis higher than
0 indicate adhesion displacement higher than the original L. rhamnosus GG, and those lower than 0 indicate adhesion displacement lower than the original
L. rhamnosus GG. Adhesion displacement significantly different from the original L. rhamnosus GG (* if 0·05 # P,0·10 and ** if P,0·05). Values are means,
with standard errors represented by vertical bars. The OL indicates the external reference L. rhamnosus strain. C. sakazakii, Cronobacter sakazakii; S. enterica
ser., Salmonella enterica serovar; C. perfringens, Clostridium perfringens; S. aureus, Staphylococcus aureus. Identification codes: AL, BL, CL, DL, EL, FL, HL, IL,
JL, KL, LL, ML and NL.
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influence their in vivo effects, underlining the importance
of control of the manufacturing process and the
food matrix. The L. rhamnosus isolates tested in the
present study were chosen to be from different products
and origins. The manufacturing process may thus have had
a significant impact on the strain properties. Often
probiotics are used in fermented dairy products or as
freeze-dried preparations. Both provide a matrix for the
micro-organisms, and previous studies have indicated
that the matrix may affect the strain properties(22,23). This,
along with the production conditions, may in part explain
the different results obtained between strain isolates when
characterising strain impact on pathogen adhesion to
mucus, although the existence of point mutations in some
of the different isolates cannot be overruled.
In addition to the differences between strains, Deepika
et al.(24) have reported that the adhesion of the L. rhamnosus
strain GG to Caco-2 cells was the highest when bacteria
collected during the early stationary phase of growth were
used. This finding suggests that the early stationary phase
may be the optimum harvest point for Lactobacillus GG to
obtain the most adhesive strain.
Though L. rhamnosus GG is one of the probiotics
subjected to the largest number of human intervention
studies, in many cases no attention has been paid to the
specific properties of the strains used. The lack of such
reports is surprising, especially considering the early
findings on changes in the in vitro properties of early
L. rhamnosus GG strains following different production
processes and a long-term series of reinoculations, sugges-
ting deterioration of adhesion properties(6) and the report
on production lot differences in an L. acidophilus strain
influencing the outcome of human intervention studies(8).
Taken together, we conclude that the original properties
used in the selection of specific probiotic strains may
indeed be influenced by industrial production processes
and conditions as well as by the food matrix used.
This finding sets important prerequisites for quality
control in probiotics. Ensuring the original properties is
especially important when the strain or product is used
in human intervention studies, as small changes may
significantly influence the outcome. The finding also
presupposes new quality-control measures for the manu-
facture of probiotics for food use to preserve the original
properties, which may have an impact on efficacy in
human studies.
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Fig. 3. Competition of the adhesion to colonic mucus of pathogenic bacteria by the tested Lactobacillus rhamnosus isolates. Results are expressed as
percentages with regard to the competition obtained with the original L. rhamnosus GG isolate donated by Professor S. Gorbach. Values on the X-axis higher than 0
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